SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| FALTISCHEK DENISE M | Chief Strategy Officer | 2026-08-26 | Option exercise | 58204 | $0 |
| FALTISCHEK DENISE M | Chief Strategy Officer | 2026-08-26 | Tax withholding | 30849 | $151K |
| FALTISCHEK DENISE M | Chief Strategy Officer | 2026-08-26 | Option exercise | 120017 | $0 |
| FALTISCHEK DENISE M | Chief Strategy Officer | 2026-08-26 | Tax withholding | 63610 | $310K |
| Gendel Mitchell | Global General Counsel | 2026-08-26 | Option exercise | 50556 | $0 |
| Gendel Mitchell | Global General Counsel | 2026-08-26 | Tax withholding | 26795 | $131K |
| Gendel Mitchell | Global General Counsel | 2026-08-26 | Option exercise | 109748 | $0 |
| Gendel Mitchell | Global General Counsel | 2026-08-26 | Tax withholding | 58167 | $284K |
| Merton Carl A | Chief Financial Officer | 2026-08-26 | Option exercise | 57380 | $0 |
| Merton Carl A | Chief Financial Officer | 2026-08-26 | Tax withholding | 31559 | $154K |
| Merton Carl A | Chief Financial Officer | 2026-08-26 | Option exercise | 111072 | $0 |
| Merton Carl A | Chief Financial Officer | 2026-08-26 | Tax withholding | 61090 | $298K |
| SIMON IRWIN D | President and CEO, Director | 2026-08-26 | Option exercise | 408605 | $0 |
| SIMON IRWIN D | President and CEO, Director | 2026-08-26 | Tax withholding | 216561 | $1.1M |
| SIMON IRWIN D | President and CEO, Director | 2026-08-26 | Option exercise | 803563 | $0 |
| SIMON IRWIN D | President and CEO, Director | 2026-08-26 | Tax withholding | 425889 | $2.1M |
| Gendel Mitchell | Global General Counsel | 2026-08-06 | Open-market buy | 2500 | $11K |
| Merton Carl A | Chief Financial Officer | 2026-08-04 | Open-market buy | 10000 | $46K |
| FALTISCHEK DENISE M | Chief Strategy Officer | 2026-08-03 | Open-market buy | 2500 | $12K |
| FALTISCHEK DENISE M | Chief Strategy Officer | 2026-07-30 | Option exercise | 26120 | $0 |
Fiscal period ending 2026-05-31 versus 2025-05-31 — view filing on EDGAR →
Regulatory and operational risks broadened materially, with new federal hemp-THC legislation, DEA rescheduling, expanded European exposure, and the BrewDog acquisition adding compounding uncertainty across compliance, integration, and market access. Intangible assets doubling to $42.8M and expanded litigation scope — now including derivative suits, securities class actions, and data privacy claims — add meaningful balance sheet and legal tail risk. Two capital-structure improvements (Nasdaq compliance restored, warrant dilution eliminated) provide partial offset but do not counterbalance the breadth of worsening across regulatory, geopolitical, and operational themes.
7 company-specific · 2 eased/removed · 2 common-mode
New 2025 federal legislation redefining hemp with total-THC standard effective November 2026 may render current products non-compliant. Materially escalates regulatory risk and product viability uncertainty.
United States regulations relating to cannabinoid products, including CBD, Delta-9 THC, THCA and other cannabinoids, are rapidly evolving, and recent federal and state legislative developments may…
New material acquisition risk: BrewDog U.S. deal dependent on regulatory approval with integration, synergy, and operational disruption risks disclosed.
Our ability to complete the BrewDog U.S. acquisition is subject to regulatory approvals, and we may face risks associated with integrating all of the acquired BrewDog businesses. The completion of…
DEA rescheduled certain marijuana to Schedule III in April 2026; broader rescheduling process ongoing with uncertain outcome. Adds concrete regulatory action and uncertainty risk.
Government regulation of the cannabis industry is evolving, including recent regulatory developments in the United States to reschedule cannabis from Schedule I to Schedule III under the Controlled…
Company expanded regulatory risk disclosure to include Europe, signaling new material market exposure and regulatory constraints beyond Canada.
Regulations constrain our ability to market and distribute our products in Canada and Europe. In Canada and Europe, there are significant regulatory restrictions on the marketing, branding, product…
Expanded litigation scope: added derivative litigation, securities class actions, data privacy/cybersecurity, product marketing/labeling, IP rights. Enhanced regulatory language emphasizing material adverse effects and expected significant ongoing costs.
Risks Related to Ongoing Litigation Claims We are subject to litigation, arbitration and demands, which could result in significant liability and costs, and impact our resources and reputation.…
Intangible assets doubled from $21.4M to $42.8M year-over-year, materially increasing impairment risk exposure and balance sheet vulnerability.
Additional impairments of our goodwill, additional impairments of our intangible and other long-lived assets, and changes in the estimated useful lives of intangible assets could have a material…
Added aluminum as specific key input and expanded geopolitical risks to include Iran hostilities, escalating supply chain vulnerability.
Significant interruptions in our access to certain supply chains for key inputs such as raw materials, aluminum, supplies, electricity, water and other utilities may impair our operations. Our…
Nasdaq delisting risk removed. Company regained compliance with minimum bid price requirement, eliminating material threat to exchange listing and market access.
Risks Related to Ownership of Our Securities Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities. On March 25, 2025, the Company received…
Removal of warrant dilution risk. 6.2M warrants at $0.42 exercise price no longer threaten capital raising or stockholder dilution post-September 2025 expiration.
The terms of our outstanding warrants may limit our ability to raise additional equity capital or pursue acquisitions, which may impact funding of our ongoing operations and cause significant…
New disclosure of geopolitical risk (Iran conflict) materially affecting European fuel/energy costs, operating expenses, margins, and energy-intensive operations (brewing, cannabis cultivation).
Geopolitical instability involving the conflict in Iran could increase fuel and energy costs in Europe and adversely affect our operations and results. Ongoing geopolitical instability in the Middle…
New disclosure of geopolitical risks (Middle East instability) causing freight cost increases and supply chain disruptions—a substantive escalation of transportation risk.
We face risks associated with the transportation of our products to consumers in a safe and efficient manner. We depend on fast, cost-effective, and efficient courier services to distribute our…
Tilray issued 1,377,334 shares of common stock in unregistered private debt-for-equity exchange transactions, exchanging equity for $6 million principal of convertible notes. This is a dilutive issuance of unregistered equity securities under Item 3.02, relying on Section 3(a)(9) exemption. The transaction materially increases share count and would affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →This is a press release disclosing Tilray's fiscal year 2026 financial results (ended May 31, 2026), filed on July 28, 2026 under Item 2.02. The filing reports record net revenue of $915.5 million, record gross profit, record adjusted EBITDA of $61.1 million, and provides fiscal 2027 guidance of $68–75 million adjusted EBITDA. The press release is attached as Exhibit 99.1 and incorporated by reference, which is the standard format for earnings releases on Form 8-K.
View raw filing on EDGAR →Tilray issued 2,638,341 shares of common stock in unregistered private debt-for-equity exchange transactions between June 15-24, 2026, exchanging $12 million principal of convertible notes for equity. This is a dilutive issuance of unregistered equity securities under Section 3(a)(9) of the Securities Act, disclosed under Item 3.02, representing material shareholder dilution and a significant capital restructuring event.
View raw filing on EDGAR →The filing discloses two unregistered equity issuances: (1) 398,666 shares issued as consideration for the Lyphe Group acquisition under Section 4(a)(2), and (2) 1,214,186 shares issued in a debt-for-equity exchange under Section 3(a)(9). Together, these represent approximately 1.6 million shares of dilutive issuance, with the debt exchange alone converting $6 million of convertible notes. This is material to investors as it increases share count and dilutes existing shareholders.
View raw filing on EDGAR →